Atossa Genetics and AAIPharma / Cambridge Major Laboratories Announce Manufacturing Agreement For Atossa’s Lead Drug Candidate Afimoxifene Gel

SEATTLE, WA – August 5, 2015 – Atossa Genetics Inc. (NASDAQ: ATOS), the Breast Health Company, announced today that it has signed manufacturing and quality agreements with AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. (AAI/CML) for the manufacturing of a clinical supply for 4-Hydroxytamoxifen, the active pharmaceutical ingredient (API) in Atossa’s leading drug candidate, Afimoxifene Gel. In May 2015, Atossa acquired from Besins Healthcare the exclusive rights to Afimoxifene Gel for the potential treatment of hyperplasia of the breast.

Topics: News & Events